Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Cancer Research UK launched a bold scheme in 2006 to give second chances to industry's de-prioritized compounds. Its first two projects have now run their course, with varying degrees of success.
Roche's bitopertin failed to improve the negative symptoms of schizophrenia in two pivotal trials, raising questions about the therapeutic potential of glycinergic neuromodulation.
A new model of company creation pioneered by Lilly, Celgene, Sanofi, Roche and others is set to deliver both clinical candidates and platform technologies.
Chronic lymphocytic leukaemia (CLL) has become a fertile testing ground for novel targeted agents, one of which may become the most lucrative haematology drug in history.